Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 7/20 | 0.45 |
| ▸ | RIPK1 | Q13546 | 2/20 | 0.44 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.44 |
| ▸ | SCD5 | Q86SK9 | 2/20 | 0.44 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.42 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | DRD2 | P14416 | 1/20 | 0.42 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21392838 | 0.80 | ROCK2 (0.52) | ROCK2ADAM17SCD5OPRM1OPRK1 | |
| SCHEMBL18510351 | 0.79 | FKBP1A (0.52) | ROCK2RIPK1ADAM17SCD5 | |
| SCHEMBL28168304 | 0.78 | ROCK2 (0.56) | ROCK2RIPK1ADAM17SCD5OPRM1 | |
| SCHEMBL19151688 | 0.78 | ADAM17 (0.54) | ROCK2RIPK1ADAM17SCD5OPRM1 | |
| SCHEMBL8542566 | 0.73 | ROCK2 (0.62) | ROCK2SCD5HSD17B10 | |
| SCHEMBL19275752 | 0.72 | THRB (0.56) | OPRM1OPRK1DRD2 | |
| SCHEMBL21389641 | 0.71 | ADAM17 (0.43) | ROCK2RIPK1ADAM17SCD5OPRM1 | |
| Acetic Acid SCHEMBL27572445 | 0.71 | ROCK2 (0.47) | ROCK2RIPK1ADAM17SCD5HSD17B10 | |
| SCHEMBL14611018 | 0.69 | NPC1 (0.45) | ROCK2RIPK1HCRTR2 | |
| SCHEMBL28056141 | 0.69 | PPID (0.74) | ROCK2OPRM1OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170042859-A1 | COMPOSITIONS AND METHODS FOR TREATING ALOPECIA | DAVID WEINSTEIN CONSULTING, INC. | 2017-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170042859-A1 | COMPOSITIONS AND METHODS FOR TREATING ALOPECIA | S100A4, FKBP4, FKBP5 | ROCK2 2053/4885RIPK1 2210/4885ADAM17 2223/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.